The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
Publications
McCarter SJ, Vijayvargiya P, Sidana S, Nault AM, Lane CE, Lehman JS, Wilson JW, Parikh SA, Nowakowski GS, Al-Kali A
A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses.
Leukemia & lymphoma 2019 Feb;60;559-561 — 2019 Feb — 559-561
Peri AM, Bisi L, Cappelletti A, Colella E, Verga L, Borella C, Foresti S, Migliorino GM, Gori A, Bandera A
Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018 07;24;785-786 — 2018 07 — 785-786
Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.
Cancer cell 2017 06 12;31;731-733 — 2017 06 12 — 731-733
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.
Respiratory medicine case reports 2017;21;27-29 — 2017 — 27-29
Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
Hematological oncology 2018 Feb;36;349-354 — 2018 Feb — 349-354